Janssen taking Legend CAR T therapy to clinic

Janssen Biotech Inc. said FDA cleared an IND for CAR T therapy JNJ-68284528 (LCAR-B38M) to treat multiple myeloma. Next half, the unit of Johnson & Johnson (NYSE:JNJ) expects to start a U.S. and European Phase Ib/II study of Legend Biotech’s therapy targeting BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269).

At last year's American Society of Clinical Oncology (ASCO) meeting, Legend reported JNJ-68284528 led to a 100% objective response rate among 19 MM patients in the first phase of the Chinese Phase I/II LEGEND-2 study. No neurotoxicities, which can plague anti-CD19 CAR T therapies, were observed...